Researchers from the University of Tsukuba identified the protein MafB as a key molecular actor in the development of FSGS. They showed that MafB-lacking mice develop FSGS and that treatment of FSGS mice with atRA, an agent known to induce the production of MafB, partially reversed the development of the disease. These findings provide new insights into a potential novel therapeutic target for FSGS.
- New technology allows scientists first glimpse of intricate details of Little Foot’s life
- Tissue, scaffold technologies provide new options for breast cancer, other diseases
- High fat diets may over-activate destructive heart disease protein
- A materials science approach to combating coronavirus
- New study proposes a low cost, high efficiency mask design